AKI - the other main type of kidney disease - can be caused by dehydration, blood loss, urinary tract obstructions such as ...
Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...
Identifying the early signs of kidney stone disease is crucial for preventing complications and managing symptoms.
Explore the disproportionate burden of chronic kidney disease in the Black community and the need for empowerment and ...
“My feet would be really swollen after uni. I used to elevate them but they weren’t getting better so my parents persuaded me ...
Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...
The prevalence of chronic kidney disease is rising globally, with millions of individuals affected. Factors such as renal illnesses, diabetes, and hypertension contribute to the growing incidence, ...
This trial demonstrated that Ozempic®, a GLP-1 receptor agonist, significantly reduces the risk of progression in chronic kidney disease and cardiovascular mortality in patients with type 2 diabetes.